<DOC>
	<DOCNO>NCT00219219</DOCNO>
	<brief_summary>The present study give information course time skeletal-related event ( SRE ) prostate cancer patient bone metastasis treat zoledronic acid 4 mg administer 15-minute infusion every 4 week maximum 15 infusion . The protocol enroll patient recent diagnosis bone metastases prostate cancer hormone-refractory , hormone-naïve still hormone-sensitive , represent entire population prostate cancer patient</brief_summary>
	<brief_title>Zoledronic Acid Prevention Skeletal-related Events Hormone Refractory Hormone-sensitive Prostate Cancer Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Criteria Patients age ≥18 year Written inform consent Histologicallyproven prostate carcinoma ECOG performance status ≤ 2 Life expectancy &gt; 6 month Newly diagnose ( ≤ 6 month prior visit 1 ) bone metastasis evidence bone scan radiograph . Patients androgen deprivation therapy ( medical therapy LHRH analogues + antiandrogens surgical castration ) go start Patients partner childbearing potential use barrier method contraception throughout study Exclusion Criteria Patients without history metastatic disease bone Prior treatment bisphosphonates SREs prior visit 2 Prior treatment calcitonin , mithramycin , gallium nitrate within 2 week prior baseline Corrected ( adjust serum albumin see Appendix 5 calculation ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/l ) Serum creatinine concentration &gt; 265 micromol/l ( 3.0 mg/dl ) calculate creatinine clearance &lt; 30 ml/minute serious underlying renal disease prior renal transplantation History malignant neoplasm within previous five year exception nonmelanomatous skin cancer satisfactorily treat Other known concurrent , severe medical disorder jeopardize life patient immediate future Patients treat systemic investigational drug ( ) and/or device ( ) within past 30 day topical investigational drug within past 7 day Known hypersensitivity zoledronic acid bisphosphonates History noncompliance medical regimen patient consider potentially unreliable ( example drug alchohol abuser ) incapable give informed consent judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>zoledronic acid</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>SRE</keyword>
</DOC>